EIP celebrates a win at Managing IP's EMEA Awards 2024

EIP has been recognised at last night's Managing IP EMEA Awards 2024 as European Patent Disputes Firm of the Year for Patent & Trademark Attorney Firms. The award marks a continued recognition of EIP’s consistent strength in European litigation as it's the third year in a row that EIP has won in this category. Magnus Hallin, CEO at EIP said: "We are proud to be recognised once again at the Managing IP EMEA Awards. The award is a testament to our team’s unwavering commitment to excellence and our innovative approach to IP litigation. It is not just a reflection of our expertise, but also of the trust our clients place in us to protect their most valuable assets. We are grateful for this honour and it motivates us to continue setting the bar high in the industry.”

Spotlight

To Injunct Or Not To Injunct?

Judge Asked To Grant A 9/10 Day Interim Injunction to Protect Bayer’s Anticoagulant Rivaroxaban Ahead of Main Judgment Pharmaceutical company, Bayer found success in its application seeking an interim injunction, lasting just 9-10 days, to protect its rivaroxaban product from the generic companies it is currently embroiled in litigation with whilst awaiting judgment on its patent covering rivaroxaban. Background This case revolves around rivaroxaban. Rivaroxaban is one of several direct oral anticoagulants available for prescription. Bayer own two patents that cover rivaroxaban. The first patent protects rivaroxaban as a compound. That patent was extended by an SPC until 1 April 2024. Up until 1 April 2024, Bayer have had the rivaroxaban market to itself, selling the product under its brand name Xarelto. Therefore, as of 2 April 2024 others would be entitled to market rivaroxaban. The second patent, EP(UK) 1 845 961 (“EP 961”), in broad terms, covers the use of rivaroxaban for the manufacture of tablets for once-daily oral administration to a human patient. EP 961 expires in January 2026. EP 961 has been subject to six actions for revocation which were joined, with the trial heard earlier this year. At trial, the Judge told the parties that judgment would be handed down in the first week of the Easter term, and in all likelihood probably on 9 April 2024, with the form of order hearing to be on the 11 or 12 April 2024. This meant that a window of 9-10 days arose whereby the compound patent would have expired but there was a possibility of a permanent injunction against the respondents restraining sales of once-daily rivaroxaban in the event that EP 961 was held valid. Bayer’s application before the Judge was to ensure that this window was kept shut until judgment on the EP 961. The Applications Before the Court The court had four applications before it. This article focuses on Bayer’s aforementioned application seeking an interim injunction against parties it is in litigation over the rivaroxaban product. Communication with the Court The Judge was critical about the parties’ communication with the court in relaying the consequence of not handing down his judgment until 9-10 days after 1 April 2024. The Judge recounted that the various claims filed with the court and eventually joined were progressed “without unusual haste”. On the first day of trial, the claimants’ counsel had stated that the claims had been case managed together so as to try to ensure that judgment could be handed down before 1 April 2024 but the Judge did not recall any information being provided about the consequence of not achieving that. Therefore, he was surprised at the scale of the interim application including the number of counsel and solicitors involved. The Judge wondered whether the deep involvement of the legal advisers meant that they had assumed everyone was clear on the significance of judgment not being handed down in time for argument on the form of order by 1 April. The Judge made it clear that he was not aware of said consequence and that had the parties communicated the issue to the Judge, the court would be in a better position to give the matter appropriate priority. He surmised that “in short, better communication with the court is desirable.” Bayer’s Interim Injunction Application The Court applied the well-known American Cyanamid principles when looking to assess the suitability of granting or rejecting Bayer’s application for an interim injunction. The parties agreed that there was a serious question to be tried which had been a question before the Court at trial and would be answered with an imminent judgment. In this case of the interim injunction, the issue between the parties concerned the balance of irreparable harm. Additionally, the Judge used the Court of Appeal’s judgment in Neurim Pharmaceuticals (1991) Limited v Generics (UK) Limited [2022] EWCA Civ 370 for guidance as to the correct approach given that there was some overlap in the facts. Decision Due to the short time that this interim injunction would be in place, the Judge was not completely convinced that both parties would suffer irreparable harm. The Judge felt that Bayer’s lost sales could be calculated easily given that their current sales were known and that they were the only ones on the market with rivaroxaban. And although there may be uncertainties that may not be quantifiable, the Judge hypothesised that these would be modest. With the respondents, the Judge was also convinced that their loss of sales could be calculated with an area under the curve calculation. The Judge suggested that a graph of each of the respondents’ sales could be notionally moved back by 9-10 days or by whichever time that the evidence may suggest is appropriate. But looking at the Court of Appeal and its emphasis on the importance of maintaining the status quo in circumstances such as those in the application before him, the Judge believed it more appropriate to grant the interim injunction until resolution of the order to be made following the imminent hand down of the judgment on the EP 961. Take Away Points A key point arising from this judgment is that communication with the Court is of upmost importance. Not only can it avoid potential wasted costs but it can also bring to the forefront any urgent issues that need addressing or that may have consequences if matters are not concluded within a certain timespan. It is easy to forget that the Court has not lived through the case and so cannot be assumed to appreciate matters which the parties have at the forefront of their minds. The judgment is available here.

Partner Promotions

EIP promotes quartet to its international partnership EIP is proud to announce an expansion of our international partnership with the promotion of four from our team: Alex Morgan, Ben Willows, Isabelle Schaller, and Sebastian Fuchs. This strategic enhancement brings our partnership to a total of 36, reflecting our global presence across the UK, Germany, Sweden, and the US. What this means for our clients: Alex Morgan has been a managing associate with EIP since 2020 and has played a key role in EIP’s team for litigation work: representing Optis against Apple, IP Bridge in its litigation against Huawei and more recently, ThroughPuter in its dispute against Microsoft. Alex has been recognised as a Managing IP ‘Rising Star’ (2022 and 2023) and is listed as a key lawyer for EIP in Legal 500’s current rankings. Ben Willows brings a wealth of experience from his time at Dyson, enhancing our patent prosecution capabilities. His track record in drafting and defending patents, coupled with successful representations in EPO and UKIPO proceedings, strengthens IP portfolios, ensuring innovations are securely protected and effectively leveraged. In our Düsseldorf office, Isabelle Schaller specialises in advising on cross-border patent infringement matters, particularly in the telecommunications sector. Her strategic approach in high-stakes litigation, including securing a preliminary injunction for the client, exemplifies our commitment to safeguarding client interests in complex technological landscapes. Sebastian Fuchs, also based in Düsseldorf, is renowned for his adept handling of contentious patent issues, including FRAND licencing and wireless technology disputes. His recognition as a ‘Rising Star’ and ‘One to Watch’ underscores his expertise in delivering forward-thinking legal solutions that protect and enhance intellectual property assets. Magnus Hallin, CEO of EIP, commented, "The expansion of our partnership in key markets signifies our ongoing commitment to excellence in patent prosecution and litigation. Alex, Ben, Isabelle, and Sebastian embody the collaborative ethos and innovative spirit at the heart of EIP. Their promotions are a testament to their outstanding contributions and the value they bring to our clients." As EIP continues to grow, our focus remains steadfast on delivering unparalleled expertise and service to our clients on high value and complex patents. The elevation of our new partners strengthens our ability to navigate the complexities of IP law, offering our clients and prospects an even greater level of support and strategic insight. We congratulate Alex, Ben, Isabelle, and Sebastian on their well-deserved promotions and look forward to their continued contributions to our clients' success.

AI and Big Data in Agritech

First published by Process Engineering - February 2024 The world’s population stands above 8 billion in 2024 and is still growing. That growth may be slowing down but nonetheless there may be another 2 billion mouths to feed in the next 50 years. Furthermore, it is predicted that the expected improvements in crop yields in that same time frame will be offset by increased disease pressure resulting from climate change. [GL1] The agricultural industry is increasingly turning to data-driven approaches to give them every advantage. What are researchers doing to take advantage of computers in the crop research and agritech space? Bioinformatics Computational genomics and other aspects of bioinformatics are incredibly important in understanding plant genomes. Typically plant research is performed on Arabidopsis thaliana, a model organism with only a small diploid genome of around 135 million base pairs which makes genetic analysis more straightforward. Unfortunately, crop plants tend to have much larger and more complex genomes. Bread wheat has a hexaploid genome of around 17 billion base pairs. Furthermore, the high percentage (close to 80%) of repetitive sequences makes gene sequence analysis more difficult. By comparison, about 50% of the human genome is repetitive sequences and that is on the higher side for mammals, let alone other eukaryotes. As such, developing new varieties and new transgenic crop plants can be very difficult. This difficulty is enhanced in jurisdictions such as the EU where GMO crops are not authorised for human consumption; so bioinformatics techniques have to be used to enhance conventional crop breeding techniques rather than making direct modifications of the plant genome. Elsewhere, though there are sign of change: the UK passed the Genetic Technology (Precision Breeding) Act for England last year – reducing the regulatory burden breeders face when making genetic modifications that could have occurred naturally through conventional breeding, but not introducing exogenous genes from other species. Similar legislation is being considered in the EU. Microbiome analysis is also a big part of the bioinformatics space. Rothamsted Research recently received a £4 million award for new computer infrastructure which will help analyse soil metagenomics, essential for understanding the soil in greater details as many of the microbes in soil cannot be readily cultivated in a lab. Considering the patent side, we can see that many of the applications filed relate to the application of machine learning approaches to genomics or disease detection. We also see filings for prediction systems to optimise the chances of breeding success based on genomic data, whether via AI techniques or more classical statistical methods. Analysis of pathogens is common, with looking for pathogen DNA or identifying pesticide resistance genes. Crop Modelling Crop modelling continues to improve and develop, as it has for decades, but there are issues with lack of open data. Crop simulation has been developed since the 1960s but a renewed interest in the field has arisen from the improved sources of data (such as from remote sensing), the increasing demand from population growth, the impact of climate change, and the application of machine learning. Looking at patent filings, development of these technologies seem to be in the application of machine learning but nonetheless, we still see filings for improvements to more classical state machines. Interestingly, the majority of filings are in China and the US. The former is to be expected given the domestic patent policy in China but it is a little surprising to see hardly any PCT 1.applications being taken forward in Europe. This may be due to the understanding of the European Patent Office’s requirements that computer software must have a technical effect in order to be patentable. As such, more abstract processes are less likely to be patentable in Europe. However, it should be understood that simulation can definitely be patented in Europe with the right claim wording, provided of course the invention has an inventive step and meets the other patentability criteria. Remote Sensing Remote Sensing generally refers to the collection of information about something from a distance but typically refers to the usage of Earth observation satellites and camera drones. Some satellites are government-owned such as the European Space Agency’s Sentinel satellites. Others are owned by private enterprise, such as Airbus’s Pleiades Neo satellites. Remote sensing from satellites has been used for decades to measure crop productivity. It has also been employed to detect and map plant diseases, which often alter the appearance and structure of the plants in such a way that is detectable through multispectral data; for example from yellowing leaves or from wilting crops altering the angular polarisation of radar scans. Satellite technologies are also relevant to livestock monitoring. Albeit satellites are less effective at this given animals tendency to wander more than plants and because most satellites only pass over the same point at most a couple of times per day as the Earth rotates. Great strides are also being made with aerial photography and the integration of that with satellite remote sensing. The massive proliferation of drone technology and improvement in digital camera technology allows farmers to survey huge areas with a high degree of accuracy. Drone footage not only provides a ground truth for human verification but can also be used more generally as a data source to integrate a big data approach. Increasingly, we can expect a democratisation of this technology to smaller and smaller farmers, particularly as nearly all of the data captured by the Copernicus satellite constellation is freely available to download on the internet. The number of patent applications filed for space-borne sensing and green applications has been rising rapidly in recent years, as shown in an EPO, ESA, ESPI joint study released in October 2022. The main developments that are being filed for are in signal processing on the software side, and AI/ML seems to be the core driver for this. Analysis and modelling of photosynthetic activity and crop productivity are also frequently mentioned in these applications, as well as weather and river/coastal observations. In summary, agritech has always been an area of significant technological advancement but data driven technologies are becoming increasingly relevant in our interconnected world. 1. Patent Cooperation Treaty or ‘international’ patent applications offer simultaneous protection in a number of signatory states [GL1]I think this is important to retain because it sets the scene for why the article matters. I have trimmed other sections to maintain the word count.

Balancing Expertise: Mellor J's Ruling on Scientific Advisers vs. Expert Evidence

Hill v Touchlight Genetics Ltd & Ors [2024] EWHC 533 (Pat) (08 March 2024) Summary This judgment concerns a novel issue in the Patents Court which arose at the second CMC in this action, regarding whether the Court should appoint a scientific adviser (“SA”) or order the exchange of expert evidence. This issue stems from a rare set of circumstances in a patent entitlement dispute. The defendants and counterclaimants, jointly “Touchlight”, own patents related to the field of biotechnology. The claimant, Dr Hill, is a molecular biologist who was a director and employee in the first defendant until she resigned in 2009. Dr Hill contends that before her employment with Touchlight, she made and disclosed to Touchlight the inventions in their patent filings that led to the patents in dispute, and that she only assigned part of these inventions under her service agreement. Consequently, she claims entitlement to joint ownership of the disputed patents and patent applications. The parties have agreed a list of issues for determination at trial, which the Court will need a thorough understanding of the technology and the inventive concepts to resolve. The Court will likely need to assess oral disclosures, their context, and the potential influence of memory on Dr. Hill, considering the significant time elapsed (16 years) since the events. Dr Hill contended that assistance could be provided to the Court by the appointment of a SA, without the need for expert evidence, while Touchlight submitted that expert evidence alone is required to address the technical aspects of the issues in dispute. The Law There is no dispute that the Court has the power to appoint a SA. (1) The issue is as to where the dividing line lies between the roles of a SA and expert evidence. Touchlight emphasised the limited role for a SA to provide non-controversial scientific background for the Court, detached from the issues in dispute, as highlighted by Birss J (as he then was) in previous cases such as Actavis (2) and Electromagnetic Geoservices (3). Touchlight presented Mellor J with a historical overview of SA appointments in patent cases, indicating that, among other things, in almost all of those cases there was no SA at first instance, since the trial was conducted before one of the category 4/5 patent judges. They emphasized that in no case was a SA appointed without evidence from technical experts and, as such, they are not intended to replace expert evidence. Dr Hill did not dispute these submissions on the law but drew attention to the fact that issues in entitlement disputes differ significantly from traditional patent infringement actions. Dr Hill relied on evidence that, subject to one exception, all entitlement disputes in the UKIPO or High Court were decided without technical expert evidence. Dr Hill’s Submissions Dr Hill argued that the Court's challenge is in understanding the technology, which requires an explanation of the fundamental science by reference to the documents and patents in issue, rather than typical expert evidence in patent actions where validity is in issue. Consequently, Dr Hill submitted that the Court would be able to comprehend the technology best via a SA. Dr Hill’s counsel emphasised the importance in this action of Dr Hill's subjective understanding of the inventions and disclosures to Touchlight, suggesting that expert evidence was unsuitable for such matters. Touchlight’s Submissions Touchlight argued against appointing a SA without also having expert evidence, deeming it unprecedented and contrary to authority. They emphasized the need for expert evidence to address disputed matters and core issues in the case, which they argued goes beyond the SA's role. Furthermore, Touchlight submitted that it is in the interest of fairness that the parties have the opportunity to present evidence and cross-examine effectively, which would be usurped by the SA’s private communication with the Court. They submitted that a category 4/5 judge should be able to understand the issues with the assistance of the expert evidence and the parties' submissions. Mellor J’s Decision Mellor J explained that both a SA and technical expert evidence serve the purpose of educating the Court on the relevant technology in patent proceedings. However, it is important to note a clear distinction: while a SA educates the Court, they do not address technical disputes, which is the role of expert evidence, where appropriate and admissible. Mellor J acknowledged that while many entitlement disputes may not require expert evidence, it ultimately depends on the specific issues involved. Mellor J anticipated technical disputes at trial, and the possibility that some may only emerge during Dr Hill’s cross-examination. Consequently, he granted permission for expert evidence rather than a SA. He agreed with Touchlight's assertion that appointing a SA without expert evidence would be unprecedented, inappropriate, and against established authority. Mellor J also ordered that the expert evidence should be sequential (as the parties jointly agreed). He directed a discussion between the experts for the purpose of seeking to reach agreement on the technical issues and preparation of a statement setting out the issues on which they agree and disagree with reasons for disagreement. Conclusion This judgment emphasises that while it is, of course, highly fact-dependent, the dividing line between the role of a SA and the role of expert evidence is that expert evidence will assist the Court to address any technical disputes. In this regard, a SA is only appointed by way of supplement, not in substitution, to the expert evidence. The judgment can be accessed here. [1] s.70(3) of the Senior Courts Act 1981 and CPR r35.15 [2] Actavis Group PTC EHF v Actavis UK Ltd [2016] EWHC 1476 (Pat) at [21] [3] Electromagnetic Geoservices ASA v Petroleum Geo-Services ASA ("EMGS") [2016] EWHC 27 (Pat) at [27]-[36]

Maternity wear retailers Seraphine Limited and Mamarella GmbH clash over serving proceedings out of the Jurisdiction

Background The Claimant Seraphine Limited (“Seraphine”) a maternity wear retailer had a trading relationship with the Defendant Mamarella GmbH (“Mamarella”), a German online retailer selling maternity wear. This relationship came to an end when Seraphine learned that Mamarella was selling maternity clothes which allegedly infringed Seraphine’s unregistered Community design rights. Seraphine issued proceedings in IPEC. On 13 June 2023, Seraphine initially attempted service on Mamarella by post in Germany without the court’s permission stating service was permitted pursuant to the 1928 Convention between His Majesty and the President of the German Reich (the “1928 Convention”). Mamarella contested service and issued an application notice on 17 July 2023 seeking: “(1) to set aside service and declare that the court has no jurisdiction on the grounds that (a) service was invalid and/or (b) none of the rules permitting service out of the jurisdiction without the court’s permission applied, and/or (2) a stay of the proceedings pending the outcome of proceedings in Germany” (para 2). On 16 October 2023 Seraphine served the proceedings again, this time under the Hague Convention via the Foreign Process Section. Mamarella contested service again and issued an application on 20 November 2023 in similar terms as the 17 July 2023 application but dropping the point on service being invalid. Legal Analysis The main issue for the deputy judge to determine was whether Seraphine was entitled to serve the proceedings out of the jurisdiction without the court’s permission. Further points on amendments to Seraphine’s pleadings and Mamarella’s alleged infringement of Seraphine’s unregistered Community designs were also discussed by the judge, albeit in less detail. Jurisdiction CPR 6.33(2B)(b) states “[t]he claimant may serve the claim form on a defendant outside of the United Kingdom where, for each claim made against the defendant to be served and included in the claim form – (b) a contract contains a term to the effect that the court shall have jurisdiction to determine that claim;”. Both parties agreed that the appropriate test to be applied when addressing the rule above was that of a “good arguable case” and was established in the Supreme Court ruling in Four Seasons Holdings Inc v Brownlie. The test is: “(i) that the claimant must supply a plausible evidential basis for the application of a relevant jurisdictional gateway; (ii) that if there is an issue of fact about it, or some other reason for doubting whether it applies, the court must take a view on the material available if it can reliably do so; but (iii) the nature of the issue and the limitations of the material available at the interlocutory stage may be such that no reliable assessment can be made, in which case there is a good arguable case for the application of the gateway if there is a plausible (albeit contested) evidential basis for it “[1] Seraphine argued that the relevant agreement was that signed by Mamarella on 11 March 2021 and Seraphine on 27 April 2021 which is titled “Seraphine Limited Terms and conditions of sale” (the “2021 Agreement”). Seraphine relied on clause 25 which contains an exclusive jurisdiction clause which states: “(a) The Contract and any dispute or claim arising out of or in connection with it or its subject matter or formation (whether or not such dispute or claim is contractual) shall be governed by, and construed in accordance with, the laws of England and Wales. (b) The Company and the Buyer irrevocably agree that, subject to the following sentence, the courts of England and Wales shall have exclusive jurisdiction over any claim or matter arising under or in connection with the Contract (whether or not such dispute or claim is contractual) and that accordingly any proceedings in respect of any such claim or matter shall be brought in such courts. Nothing in the proceedings [sic] sentence shall limit the Company’s right to take proceedings against the Buyer in any other court of competent jurisdiction”(para 14). Mamarella’s response was that the exclusive jurisdiction clause did not apply because there was no contract between the parties for all purchases made after the signing of the 2021 Agreement. The judge further discussed the terms of the 2021 Agreement in dispute and decided on the balance of probabilities that Seraphine properly construed the 2021 Agreement to state that all subsequent orders placed by Mamarella were “Orders and led to the creation of Contracts which incorporated the Terms, and hence the exclusive jurisdiction clause” (para 21). Hence, the judge found that Seraphine had the stronger argument and a good arguable case for the purpose of CPR 6.22(2B)(b). Accordingly, Seraphine was permitted to serve the proceedings out of the jurisdiction without the court’s permission. Amendments to the Pleadings and Infringement Seraphine wanted to amend their Particulars of Claim to rely on 2015 and 2019 terms and make allegations of infringement on nine new designs prior to the 2021 Agreement. Seraphine claims Mamarella was subject to either one of the previous agreements when Mamarella placed orders through Seraphine’s TradeWeb platform. Mamarella disagreed and argued that orders using the TradeWeb platform were not subject to any version of Seraphine’s terms. Surprisingly, Seraphine was not able to provide evidence that any version of the terms was on the TradeWeb platform. Consequently, the judge held that Seraphine did not have a strong argument to rely on the 2015 and 2019 terms and failed to satisfy the test under CPR 6.33(2B)(b), and could not seek to introduce the nine designs based on said terms. Further arguments were put forth by Mamarella regarding the amendments to the pleadings and the judge proposed that Seraphine provides Mamarella with a revised draft Amended Particulars of Claim in agreement with the above points, and he would adjudicate if a dispute arose. Stay of Proceedings and the 1928 Convention The judge did not find it necessary to consider the Defendant’s application for permission to rely on evidence of German law given the Defendant withdrew its application for a stay of proceedings (with the option to restore the application for a stay following the German proceedings) on the basis of forum non conveniens. Also, the parties did not further seek guidance on the validity of the 1928 Convention. Comment This is a case which once again highlights the importance of drafting unambiguous contract terms. In this instance, more clarity of the terms of the 2021 Agreement would have assisted in proving that the Defendant was subject to the exclusive jurisdiction clause and that the Claimant was allowed to serve proceedings outside of the jurisdiction without the court’s permission. Decision can be found here. [1] Four Seasons Holdings Inc v Brownlie [2017] UKSC 80 and Goldman Sachs International v Novo Banco SA [2018] UKSC 34

Updates

EIP celebrates a win at Managing IP's EMEA Awards 2024

EIP has been recognised at last night's Managing IP EMEA Awards 2024 as European Patent Disputes Firm of the Year for Patent & Trademark Attorney Firms. The award marks a continued recognition of EIP’s consistent strength in European litiga...

To Injunct Or Not To Injunct?

Judge Asked To Grant A 9/10 Day Interim Injunction to Protect Bayer’s Anticoagulant Rivaroxaban Ahead of Main Judgment Pharmaceutical company, Bayer found success in its application seeking an interim injunction, lasting just 9-10 days, to prot...

Partner Promotions

EIP promotes quartet to its international partnership EIP is proud to announce an expansion of our international partnership with the promotion of four from our team: Alex Morgan, Ben Willows, Isabelle Schaller, and Sebastian Fuchs. This strategic en...

Company

EIP celebrates a win at Managing IP's EMEA Awards 2024

EIP has been recognised at last night's Managing IP EMEA Awards 2024 as European Patent Disputes Firm of the Year for Patent & Trademark Attorney Firms. The award marks a continued recognition of EIP’s consistent strength in European litiga...

To Injunct Or Not To Injunct?

Judge Asked To Grant A 9/10 Day Interim Injunction to Protect Bayer’s Anticoagulant Rivaroxaban Ahead of Main Judgment Pharmaceutical company, Bayer found success in its application seeking an interim injunction, lasting just 9-10 days, to prot...

Partner Promotions

EIP promotes quartet to its international partnership EIP is proud to announce an expansion of our international partnership with the promotion of four from our team: Alex Morgan, Ben Willows, Isabelle Schaller, and Sebastian Fuchs. This strategic en...

EIP Talks Podcast

Resources

What's Next For Medtech?

Medical technology is booming. Statistics from the EPO show that medtech and healthcare patents have been the leading area of innovation for many years. It has always been an innovative area but medtech is now home to a growing trend for different te...